Among the 396 patients, 110 (28%) had a KRAS G12C mutation identified at the time of initial NSCLC diagnosis, and 286 (72%) had a KRAS G12C mutation identified later in their disease course. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.